NEW YORK – Namocell said on Thursday that it has signed an agreement with Germany-based manufacturer OLS OMNI Life Science to distribute Namocell's Single Cell Dispensers in Germany and Austria.
NamoCell's microfluidic-based cell platform dispenses single cells into a 96-well plate in less than a minute.
Financial details of the agreement were not disclosed.
Namocell's "single cell isolation instruments are a game-changer for cell line engineering and development, CRISPR, single-cell genomics, antibody development and other single-cell applications," Andreas Friese, chief operating officer of OLS, said in a statement. "We look forward to offering an expanded cell research portfolio to further strengthen our position as a partner in cell research."
Namocell previously signed an agreement with Takara Bio and HepaTx in February 2020 to apply the Single-Cell Dispenser tool for single-cell genomics for late-stage liver disease.